AstraZeneca's Early-Stage Lung Cancer Tagrisso Drug Approved in China
By Sabela Ojea
AstraZeneca PLC said Wednesday that its Tagrisso medicine has
been approved in China for the treatment of early lung cancer.
The U.K.-based pharmaceutical giant said Tagrisso is the first
such drug to have received approval in China, as well as the only
one to have shown efficacy against the disease in a global
The FTSE 100 company added that the approval is based on the
positive results coming from the Adaura Phase 3 trial, where
Tagrisso was proven to reduce the risk of disease recurrence or
death by 80%.
Write to Sabela Ojea at firstname.lastname@example.org; @sabelaojeaguix
(END) Dow Jones Newswires
April 14, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.